menu

Direct Anticoagulants in Children: Application of Clinical Trial findings in Practice

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing the Risk of Recurrent VTE in Children

Direct Anticoagulants in Children: Application of Clinical Trial findings in Practice

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Clinicians are unaware of the risk of recurrent VTE in children, resulting in not only an increase in the overall recurrence of VTE, but the associated healthcare costs. Results from recent clinical trials examining therapeutic options to prevent recurrent VTE in pediatric patients are relatively unknown among healthcare professionals. The management of the recurrent risk of VTE often includes a transition of care of anticoagulation therapy from the acute to post-acute setting, which is relatively new to many pediatric healthcare professionals. This program discusses how pediatric healthcare professionals can assess and reduce the risk of venous thromboembolism in children.

  • Target Audience

    This activity has been designed to meet the educational needs of the multidisciplinary team of physicians, nurses and pharmacists as well as other clinicians involved in the care of pediatric patients with venous thromboembolic disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the unmet medical need and associated dynamics of recurrent VTE in pediatric patients which impact the quality and total cost of care;
    • Analyze current treatment options for patients at risk for recurrent VTE in the pediatric population, relative to the latest clinical trials;
    • Identify recurrent VTE anticoagulation management strategies for pediatric patients undergoing a transition of care from the acute to post-acute setting.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 hours of Nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of Pharmacy contact hours. 

    The Universal Activity Number for this program is UAN JA0006235-0000-22-021-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty has reported relationships with ineligible companies:

    Neil Goldenberg, MD, PhD, faculty for this educational event, receives or has received consulting fees from Anthos Therapeutics, Bayer, Boehringer-lngelheim, Competitive Drug Development International, Daiichi Sankyo Inc., Novartis, and the Academic Research Organization CPC Clinical Research.

    Julie Jaffray, MD, MS, faculty for this educational event, has received consulting fees from Bayer. 

    Riten Kumar, MD, MSc, faculty for this educational event, has received consulting fees from Bayer. 

    Leslie Raffini, MD, MSCE, faculty for this educational event, has received consulting fees from Genentech, Janssen, and Boehringer Ingelheim.

    Guy Young, MD, faculty and chair for this educational event, has received consulting fees from Apcintex, BioMarin, Genentech/Roche, Grifols, Novo Nordisk, Pfizer, Rani, Sanofi Genzyme, Spark, and Takeda; and received research funding from Genentech, Grifols, and Takeda.

    All the relevant financial relationships for these individuals have been mitigated.

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Prerna Poojary, PhD, OTR/L, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Acknowledgment

    This activity is supported by an independent educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 6/3/2022 through 6/3/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.


    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
Schedule7 Dec 2022